Use of GnRH depot analogue in the treatment of uterine fibroids

Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot Gn-RH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dry...

Full description

Saved in:
Bibliographic Details
Published inActa Europaea fertilitatis Vol. 21; no. 4; p. 185
Main Authors Auber, G, Ricci, G, Barciulli, F, Pregazzi, R, D'Ancona, R L, Toffoletti, F G
Format Journal Article
LanguageEnglish
Published Italy 01.07.1990
Subjects
Adult
Amino Acid Sequence
Buserelin - adverse effects
Buserelin - analogs & derivatives
Buserelin - pharmacokinetics
Buserelin - therapeutic use
Estradiol - blood
Female
Follicle Stimulating Hormone - blood
Gonadotropin-Releasing Hormone - analogs & derivatives
Goserelin
Humans
Injections, Subcutaneous
Luteinizing Hormone - blood
Middle Aged
Molecular Sequence Data
Ovary - drug effects
Pituitary Gland - drug effects
Progesterone - blood
Prolactin - blood
Thyroxine - blood
Triiodothyronine - blood
Uterine Neoplasms - drug therapy
Uterine Neoplasms - metabolism
Uterine Neoplasms - pathology
Uterus - pathology
Online AccessGet more information

Cover

More Information
Summary:Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot Gn-RH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dryness, hysteroscopic endometrial atrophy, and hormonal values (FSH, LH, E2), was seen in all patients. After only two months of treatment, a significant reduction was noted in the size of the fibroid, being even greater than that in the following four months. Only one patient in the series underwent surgery. General tolerability of the drug was optimal. These data suggest the efficiency of this type of treatment in obtaining a significant reduction of fibroid volume as well as subjective symptomatology. The cost-benefit ratio is optimal, allowing postponement of surgery and the possibility of vaginal, as opposed to abdominal, hysterectomy and affronting problems of anaesthesiology and post-operative recovery for patients "at risk".
ISSN:0587-2421